Valeant Pharmaceuticals International Inc. signage is displayed outside the company's headquarters in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg Valeant had $10 million in coverage with AIG Insurance Co. of Canada and $140 million in excess coverage from various other insurance companies. The policies include coverage for securities claims, and Valeant claimed that the shareholders' claims fall under that category, but the insurance companies disagreed. Valeant sued various insurance companies for breach of contract. (Credit: Ron Antonelli)

A federal judge in Trenton, New Jersey, ruled that potential insider-trading claims stemming from Valeant Pharmaceuticals' failed takeover of Allergan Inc. are covered under a directors and officers, or D&O, policy.

Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader

  • All PropertyCasualty360.com news coverage, best practices, and in-depth analysis.
  • Educational webcasts, resources from industry leaders, and informative newsletters.
  • Other award-winning websites including BenefitsPRO.com and ThinkAdvisor.com.
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Charles Toutant

Charles Toutant is a litigation writer for the New Jersey Law Journal.